Neuroendocrine Hepatic Tumors: Summary of Patient Selection, Response and Toxicity of Radioembolization in 281 Patients

Lowell Anthony
MD, FACP, New Orleans, LA, USA

Abstract

Debulking neuroendocrine hepatic metastases is commonplace as both symptoms and disease are better controlled. The challenge in clinical decision making includes patient selection, timing and procedure. Extirpation, radiofrequency ablation, hepatic artery chemoembolization, bland embolization and radioembolization are techniques widely available in the U.S. For patients undergoing intrahepatic therapies, procedure selection is based not only on disease bulk but also on disease location. From 8 published studies, the outcomes of 281 patients who underwent radioembolization were reviewed. Symptomatic improvement occurs within 3 months in approximately half the patients. Partial biochemical responses (>50% reduction from baseline) using chromogranin A occur in two thirds of subjects as 2 centers have observed. Disease control (complete + partial + stable responses) is reported in 50-100% of patients. The median time to progression is 11.1 months in one report. Six centers report a median survival ranging from 14 to 70 months. One, 2 and 3 year survival ranges from 2 reports are 86-100%, 57-58% and 47-57%, respectively.

As more choices become available in controlling neuroendocrine disease, optimally combining debulking procedures such as radioembolization with systemic therapy is challenging. Using infusional 5-FU with radioembolization can be done safely but added benefit remains uncertain. Prior hepatic artery chemoembolization may not be a contraindication to radioembolization. Future trials are needed to guide the practitioner in using radiation sensitizers with radioembolization.

Introduction

Neuroendocrine tumors (NETs) are increasing in incidence and are the second most prevalent malignancy of the gastrointestinal tract [1]. These tumors comprise a heterogeneous group that involves every organ system and ranges from the benign to the most aggressive. Common clinical presentations include misdiagnoses and delay in diagnosis that result in the majority of patients presenting with either locally advanced or metastatic disease. As treatment options such as radioembolization, peptide-receptor radiotherapy and targeted therapies are increasing, survival is improving with single-institutional outcomes significantly better than population-based studies and multi-disciplinary care necessary [2,3].

A common cause of death in patients with NETs is liver failure due to hepatic replacement by tumor [4]. As liver metastases are a poor prognostic feature, treatment goals include not only controlling symptoms but also the disease while improving the quality of life. For patients with either well-differentiated or intermediate-grade neoplasms, debulking with either cytoreductive surgery, hepatic embolization or radiofrequency ablation offer the potential for meaningful improvement in symptom palliation by reducing hormonal levels and overall tumor burden (see Figure 1).

For patients that are non-surgical candidates, liver regional therapy options include hepatic embolization, chemoembolization, hepatic perfusion and brachytherapy [5]. These regional arterial therapies are administered through angiographic catheters and delivered into a segmental, lobar or whole liver distribution. Particle embolization with or without chemotherapy has become standard therapy for patients with extensive liver involvement. While data suggest that the addition of intra-arterial cytotoxic chemotherapy improves outcome for patients with pancreatic NETs, there are conflicting data for patients with midgut NETs as the target populations and techniques are too heterogeneous and inconsistent, respectively [6]. The post-embolization syndrome (malaise, fever, pain and nausea) that predictably occurs following a bland or chemoembolization, requires a short hospitalization stay for support (intravenous fluids, antibiotics, antiemetics and analgesics).

Radioembolization is a form of brachytherapy that uses the hepatic artery as a conduit to selectively deliver the β-emitteryttrium-90.

*Corresponding author: Lowell Anthony, MD, FACP. New Orleans, LA, USA, E-mail: LAntho@lsuhsc.edu

Received April 26, 2011; Accepted May 26, 2011; Published June 15, 2011


Copyright: © 2011 Anthony L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This type of radiation is effective and well tolerated in cancer patients with hepatic metastases [7,8]. Since stasis of blood flow is not a goal of radioembolization, patients do not generally require hospitalization for management of symptoms and complications. In the absence of prospective multi-center head-to-head comparator trials assessing the efficacy and safety of embolization procedures vs regional brachytherapy, deciding between the two procedures is determined more by individual patient characteristics and/or the experience of the managing physician/team.

Therapies that anatomically or physiologically disrupt blood vessels such as embolization/chemoembolization or VEGF inhibitors may affect the efficacy of subsequent agents intra-arterially delivered. Sequencing bland- or chemoembolization with radioembolization has been reported [9]. As one intrahepatic therapy may influence another, there are no studies to guide the optimal sequencing of these treatments. For non-secretory tumors, signs and symptoms of hepatomegaly can be, at least in part, that which brings the patient to seek medical attention. Patients considered for radioembolization include those with a Karnofsky Performance Status ≥ 60%, hepatic dominant metastatic and unresectable metastatic disease with an expected survival of at least 3 months [17]. Symptomatic syndromic patients on depot somatostatin analogs may benefit from supplemental intravenous or subcutaneous formulation to lower the risk of a prolonged hypotensive or carcinoid crisis. For patients whose symptoms are well-controlled or absent, the prophylactic use of immediate release octreotide to supplement the depot formulation is unclear.

Radioembolization is contraindicated if (1) an uncorrectable and clinically significant (≥ 30 Gy radiation exposure to extra-hepatic sites) extra-hepatic shunt is present on the pretreatment 99mTc macroaggregated albumin (MAA) scan (2) extensive hepatic tumor burden with limited hepatic reserve (3) elevated total bilirubin (> 2.0 mg/dl) (4) portal vein occlusion in the absence of a selective or superselective angiographic technique feasibility [17]. Combining radioembolization with cytotoxic chemotherapy,[13,18-20] targeted therapies and other forms of radiation therapy (external beam or infusional therapy with I-131 MIBG [21] or Lu-177 tetraazacyclododecane tetraaetic acid-d-Phe(1)-Tyr(3)-octreotide (DOTATOC)is unclear and are the topics for clinical investigations not only in NETs but also in other malignancies.

### Patient selection

Stage IV neuroendocrine tumor patients present with variable degrees of hepatic involvement that can be focal or diffuse. For non-secretory tumors, signs and symptoms of hepatomegaly can be, at least in part, that which brings the patient to seek medical attention. Patients considered for radioembolization include those with a Karnofsky Performance Status ≥ 60%, hepatic dominant metastatic and unresectable metastatic disease with an expected survival of at least 3 months [17]. Symptomatic syndromic patients on depot somatostatin analogs may benefit from supplemental intravenous or subcutaneous formulation to lower the risk of a prolonged hypotensive or carcinoid crisis. For patients whose symptoms are well-controlled or absent, the prophylactic use of immediate release octreotide to supplement the depot formulation is unclear.

### Response assessments

Objective evidence of response is more likely to be either radiographic responses or survival analysis using Kaplan-Meier statistics to calculate time to progression (TTP) and median overall survival.
survival (OS). Survival percentages at fixed time points such as 1, 2 and 3 years may also be reported (see Table 1).

**Symptomatic:** Improvement in syndrome or symptom control is not well documented as many of these reports are retrospective and performed without extra-mural funding. The prospective single center trials are more likely to have a small patient number secondary to the rarity of the condition. An increase in quality of life occurred at 3 months post therapy and gradually returned to baseline one year later [11]. Another study reported symptom improvement in approximately half the patients at 3 and 6 months post therapy [13].

**Biochemical:** Biochemical markers are infrequently monitored as part of routine care in many centers. Obtaining baseline biomarker levels is challenging even with extra-mural support and/or funding. Another variable is the heterogeneity in the patient populations with respect to primary site and which biochemical marker is over secreted. The scarcity of this data (see Table 1) as surrogate endpoints diminishes their robustness. One study (N=9 small bowel NETs) did demonstrate a 60-70% partial response rate using chromogranin A levels at 3 and 6 months with similar results confirmed by another group (N=9 with 4 small bowel NETs) [11,13].

**Radiographic:** Disease control (complete response + partial response + stable disease) is a meaningful measure if progressive disease patients were selected and/or the procedure is relatively non-toxic. The mean (+/− S.E., range) disease control rate of the 281 patients in the literature is 75% (+/− 6%, 50-100%) with some reports of complete responses that are more likely to occur in patients with low bulk disease (see Table 1).

**Survival:** The variability in survival endpoint reporting makes it difficult to compare outcomes across centers. The median time to progression (TTP) reported by only one center was 11.1 months [11]. The “median” median overall survival (OS) from six centers was 29.4 months (+/− 6.7 mos, S.E.) (see Table 1). The respective 1, 2 and 3 year survival statistics from 2 centers were: 86%, 58%, 47% and 100%, 57%, 57% [10,11].

**Toxicity**

Significant toxicity (CTCae 3.0 grade 3-4) following 90Y-microsphere treatment is mostly fatigue (6.5%), nausea (3.2%) and pain (2.7%) with 1 report of ascites but 66% of patients reported no severe side effects in the largest multi-center retrospective report [12]. These side effects are similar to those observed from radioembolization in other disease states [22]. Comparing side effects between radioembolization and other hepatic artery treatments such as chemoembolization, favors radioembolization for patients with primary liver cancer [23]. Extrahepatic complications occur but are infrequent based on the selection and preparation of patients [24-30,22,31,22,12,33-35]. Hepatic abscess have also been reported in NETs [36]. Techniques are described to further minimize complications [37-39].

**Conclusions**

Debulking liver disease in NETs patients is commonly done either for symptom control or at the time of local progression. Radioembolization preferentially delivers high radiation doses to hepatic NET metastases and is effective, safe and comparable to other local therapies in this patient population. Though extrahepatic complication are possible; the benefits outweigh the risks of adverse events from further disease progression. Improvement in symptoms can be expected within 3 months of the procedure with durability for another 6-9 months. Biochemical markers are more likely to decrease by 50% in the first 90 day period in the majority of patients and not progress over the next 6 months. Disease control is to be expected in 75% of subjects and a 1-yr survival rate of 85-100%. Median overall survival is approximately 2.5 years and reflects the relative advanced patient receiving radioembolization as salvage therapy.

Further progress is necessary in improving outcomes. Future efforts in identifying additive or synergistic combination therapies with radioembolization is on the immediate forefront not only for NET patients but in hepatocellular cancer, colorectal cancer and other malignancies involving the liver. With its safety and efficacy well-established in NET patients, using radioembolization earlier in disease management when complete radiographic responses occur, may allow further improvements in overall survival.

**References**


